Exact Mass: 1150.535656

Exact Mass Matches: 1150.535656

Found 33 metabolites which its exact mass value is equals to given mass value 1150.535656, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

1alpha,3beta,22R-Trihydroxyergosta-5,24E-dien-26-oic acid 3-O-b-D-glucoside 26-O-[b-D-glucosyl-(1->4)-b-D-glucosyl-(1->2)-6-acetyl-b-D-glucosyl] ester

6-[(Acetyloxy)methyl]-3-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl (2Z)-5-hydroxy-6-(3-hydroxy-2,15-dimethyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-en-14-yl)-2,3-dimethylhept-2-enoic acid

C54H86O26 (1150.5407056)


1alpha,3beta,22R-Trihydroxyergosta-5,24E-dien-26-oic acid 3-O-b-D-glucoside 26-O-[b-D-glucosyl-(1->4)-b-D-glucosyl-(1->2)-6-acetyl-b-D-glucosyl] ester is found in fruits. 1alpha,3beta,22R-Trihydroxyergosta-5,24E-dien-26-oic acid 3-O-b-D-glucoside 26-O-[b-D-glucosyl-(1->4)-b-D-glucosyl-(1->2)-6-acetyl-b-D-glucosyl] ester is a constituent of Physalis peruviana (Cape gooseberry). Constituent of Physalis peruviana (Cape gooseberry). 1alpha,3beta,22R-Trihydroxyergosta-5,24E-dien-26-oic acid 3-O-b-D-glucoside 26-O-[b-D-glucosyl-(1->4)-b-D-glucosyl-(1->2)-6-acetyl-b-D-glucosyl] ester is found in fruits.

   

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

2-{[(1-{19-benzyl-12,15,18,21,24-pentahydroxy-16-[2-(C-hydroxycarbonimidoyl)ethyl]-13-[(C-hydroxycarbonimidoyl)methyl]-22-[(4-methoxyphenyl)methyl]-7,8-dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosa-11,14,17,20,23-pentaene-10-carbonyl}pyrrolidin-2-yl)(hydroxy)methylidene]amino}-5-carbamimidamido-N-[(C-hydroxycarbonimidoyl)methyl]pentanimidate

C52H74N14O12S2 (1150.5051804)


   

CDP-DG(a-17:0/LTE4)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-{[(2R)-1-({[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)-3-[(14-methylhexadecanoyl)oxy]propan-2-yl]oxy}-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C52H88N4O18P2S (1150.5289288)


CDP-DG(a-17:0/LTE4) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(a-17:0/LTE4), in particular, consists of one chain of one 14-methylhexadecanoyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).

   

CDP-DG(LTE4/a-17:0)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2R)-3-({[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)-2-[(14-methylhexadecanoyl)oxy]propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C52H88N4O18P2S (1150.5289288)


CDP-DG(LTE4/a-17:0) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(LTE4/a-17:0), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of 14-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).

   

CDP-DG(i-17:0/LTE4)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-{[(2R)-1-({[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)-3-[(15-methylhexadecanoyl)oxy]propan-2-yl]oxy}-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C52H88N4O18P2S (1150.5289288)


CDP-DG(i-17:0/LTE4) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(i-17:0/LTE4), in particular, consists of one chain of one 15-methylhexadecanoyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).

   

CDP-DG(LTE4/i-17:0)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2R)-3-({[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(2-hydroxy-4-imino-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)-2-[(15-methylhexadecanoyl)oxy]propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C52H88N4O18P2S (1150.5289288)


CDP-DG(LTE4/i-17:0) is an oxidized CDP-diacylglycerol (CDP-DG). Oxidized CDP-diacylglycerols are glycerophospholipids in which a cytidine diphosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized CDP-diacylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, CDP-diacylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. CDP-DG(LTE4/i-17:0), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of 15-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized CDP-DGs can be synthesized via three different routes. In one route, the oxidized CDP-DG is synthetized de novo following the same mechanisms as for CDP-DGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the CDP-DG backbone, mainly through the action of LOX (PMID: 33329396).

   
   
   
   
   
   

(3beta,20S)-pregn-5-ene-3,20-diol 3-[O-2-O-acetyl-beta-digitalopyranosyl-(1->4)-beta-cymaropyranoside] 20-[O-beta-glucopyranosyl-(1->6)-O-beta-glucopyranosyl-(1->2)-digitalopyranoside]

(3beta,20S)-pregn-5-ene-3,20-diol 3-[O-2-O-acetyl-beta-digitalopyranosyl-(1->4)-beta-cymaropyranoside] 20-[O-beta-glucopyranosyl-(1->6)-O-beta-glucopyranosyl-(1->2)-digitalopyranoside]

C55H90O25 (1150.577089)


   
   

3-O-[beta-D-glucopyranosyl(1->2)-beta-D-glucopyranosyl(1->2)-beta-D-glucopyranosyl]-28-O-beta-D-glucopyranoside medicagenate

3-O-[beta-D-glucopyranosyl(1->2)-beta-D-glucopyranosyl(1->2)-beta-D-glucopyranosyl]-28-O-beta-D-glucopyranoside medicagenate

C54H86O26 (1150.5407056)


   

23-O-beta-D-glucopyranosyl-3beta,16alpha-dihydroxyolean-12-en-23alpha,28beta-dioic acid 28-O-{[beta-D-glucopyranosyl(1->2)][beta-D-glucopyranosyl(1->6)]}-beta-D-glucopyranoside|dianversicoside F

23-O-beta-D-glucopyranosyl-3beta,16alpha-dihydroxyolean-12-en-23alpha,28beta-dioic acid 28-O-{[beta-D-glucopyranosyl(1->2)][beta-D-glucopyranosyl(1->6)]}-beta-D-glucopyranoside|dianversicoside F

C54H86O26 (1150.5407056)


   

16alpha,22alpha-diacetoxy-3beta-O-(beta-D-xylopyranosyl-(1?2)-beta-D-glucopyranosyl-(1?4)-[beta-D-glucopyranosyl-(1?2)]-alpha-L-arabinopyranosyl)-olean-12-en-28-ol

16alpha,22alpha-diacetoxy-3beta-O-(beta-D-xylopyranosyl-(1?2)-beta-D-glucopyranosyl-(1?4)-[beta-D-glucopyranosyl-(1?2)]-alpha-L-arabinopyranosyl)-olean-12-en-28-ol

C54H86O26 (1150.5407056)


   

3-O-beta-D-glucopyranosyl-(1?6)-beta-D-glucopyranosyloleane29-hydroxy-12-en-23,28-dioic acid 28-O-beta-D-glucopyranosyl-(1?6)-beta-D-glucopyranoside|cowpeasaponin II

3-O-beta-D-glucopyranosyl-(1?6)-beta-D-glucopyranosyloleane29-hydroxy-12-en-23,28-dioic acid 28-O-beta-D-glucopyranosyl-(1?6)-beta-D-glucopyranoside|cowpeasaponin II

C54H86O26 (1150.5407056)


   

chloragin|tigogenin-3-O-alpha-L-rhamnopyranosyl-(1-4)-beta-D-glucopyranosyl-(1-3)-beta-D-xylopyranosyl-(1-4)-beta-D-glucopyranosyl-(1-4)-beta-D-xylopyranoside|tigogenin-3-O-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucopyranosyl-(1->3)-beta-D-xylopyranosyl-(1->4)-beta-D-glucopyranosyl-(1->4)-beta-D-xylopyranoside

chloragin|tigogenin-3-O-alpha-L-rhamnopyranosyl-(1-4)-beta-D-glucopyranosyl-(1-3)-beta-D-xylopyranosyl-(1-4)-beta-D-glucopyranosyl-(1-4)-beta-D-xylopyranoside|tigogenin-3-O-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucopyranosyl-(1->3)-beta-D-xylopyranosyl-(1->4)-beta-D-glucopyranosyl-(1->4)-beta-D-xylopyranoside

C55H90O25 (1150.577089)


   

8a-[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxycarbonyl-2,3,9-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

NCGC00380216-01!8a-[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxycarbonyl-2,3,9-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C54H86O26 (1150.5407056)


   
   

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin trifluoroacetate salt

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin trifluoroacetate salt

C52H74N14O12S2 (1150.5051804)


   

Pyrvinium pamoate

Pyrvinium pamoate

C75H70N6O6 (1150.535656)


D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics

   
   
   
   
   

Dianversicoside F

Dianversicoside F

C54H86O26 (1150.5407056)


A pentacyclic triterpenoid saponin isolated from the aerial parts of Dianthus versicolor. It has been shown to exhibit cytotoxic activity against a panel of cancer cell lines.

   

8a-[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxycarbonyl-2,3,9-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

8a-[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxycarbonyl-2,3,9-trihydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C54H86O26 (1150.5407056)


   

5-hydroxy-2-({2-hydroxy-6-[(1-{1-[(5-hydroxy-4-methoxy-6-methyl-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl)oxy]ethyl}-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl)oxy]-4-methoxyoxan-3-yl}oxy)-4-methoxy-6-methyloxan-3-yl acetate

5-hydroxy-2-({2-hydroxy-6-[(1-{1-[(5-hydroxy-4-methoxy-6-methyl-3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}oxan-2-yl)oxy]ethyl}-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl)oxy]-4-methoxyoxan-3-yl}oxy)-4-methoxy-6-methyloxan-3-yl acetate

C55H90O25 (1150.577089)


   

[(3r,4r,5r,6s)-5-{[(2s,3r,4r,5r,6r)-5-{[(2s,3r,4s,5r)-4-{[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-methoxyoxan-2-yl]oxy}-3,5-dihydroxyoxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-hydroxy-6-{[(2s,5s,6r,9s,12r,13r,16s,18r)-2,6,13,17,17-pentamethyl-6-(4-methylpent-4-enoyl)-8-oxo-7-oxapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-1(20)-en-16-yl]oxy}oxan-3-yl]oxidanesulfonic acid

[(3r,4r,5r,6s)-5-{[(2s,3r,4r,5r,6r)-5-{[(2s,3r,4s,5r)-4-{[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-methoxyoxan-2-yl]oxy}-3,5-dihydroxyoxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-hydroxy-6-{[(2s,5s,6r,9s,12r,13r,16s,18r)-2,6,13,17,17-pentamethyl-6-(4-methylpent-4-enoyl)-8-oxo-7-oxapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icos-1(20)-en-16-yl]oxy}oxan-3-yl]oxidanesulfonic acid

C53H82O25S (1150.4865642)


   

(2r,3s,5s)-2,3,4,5-tetrahydroxy-6-({[(2s,3s,5s)-2,3,4-trihydroxy-6-(hydroxymethyl)-5-{[(3s,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}methyl)oxan-2-yl (1r,3as,5ar,5br,7ar,9r,11ar,11br,13ar,13br)-1-(but-1-en-2-yl)-5a,5b,8,8,11a-pentamethyl-9-{[(2s,3s,5s)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-hexadecahydrocyclopenta[a]chrysene-3a-carboxylate

(2r,3s,5s)-2,3,4,5-tetrahydroxy-6-({[(2s,3s,5s)-2,3,4-trihydroxy-6-(hydroxymethyl)-5-{[(3s,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}methyl)oxan-2-yl (1r,3as,5ar,5br,7ar,9r,11ar,11br,13ar,13br)-1-(but-1-en-2-yl)-5a,5b,8,8,11a-pentamethyl-9-{[(2s,3s,5s)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-hexadecahydrocyclopenta[a]chrysene-3a-carboxylate

C55H90O25 (1150.577089)